| Bioactivity | BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM)[1][2]. | ||||||||||||
| Invitro | Since PD-1 mediated the exhaustion of natural killer (NK) cell by binding to its ligand PD-L1, BMS-1 (PD-1/PD-L1 inhibitor 1) (1 μM, 3 days) is used to disturb the interaction between PD-1 and PD-L1. Dexamethasone induced increase of PD-1 expression and decrease of cytotoxicity of the co-cultured NK92 cells are reversed by BMS-1[1]. BMS-1, a small-molecule immune checkpoint inhibitor of PD-1/PD-L1, can be used as a therapeutic strategy for tumor immunotherapy[2]. Cell Cytotoxicity Assay[1] Cell Line: | ||||||||||||
| Name | BMS-1 | ||||||||||||
| CAS | 1675201-83-8 | ||||||||||||
| Formula | C29H33NO5 | ||||||||||||
| Molar Mass | 475.58 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|